Drug · CHEMBL1069

VALSARTAN

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. VALSARTAN. Drugs and targets, record CHEMBL1069. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1069

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: VALSARTAN; ChEMBL
ChEMBL ID: CHEMBL1069; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Diovan, Prexxartan, Valsartan component of agsav301, Valsartan component of byvalson, Valsartan component of copalia, Valsartan component of copalia-hct, Valsartan component of dafiro, Valsartan component of dafiro-hct, Valsartan component of diovan hct, Valsartan component of entresto, Valsartan component of exforge, Valsartan component of exforge hct, Valsartan component of imprida, Valsartan component of imprida-hct, Valsartan component of valturna; ChEMBL
Other names: CGP 48933, CGP-48933, NSC-758927; ChEMBL
DrugBank: DB00177; DrugBank
InChIKey: ACWBQPMHZXGDFX-QFIPXVFZSA-N; ChEMBL
Open Targets' highest stage: Approval, for 7 of its 65 diseases, from ATC, DailyMed, EMA Human Drugs, PMDA and TTD; Open Targets

Targets1

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
AGTR1	Type-1 angiotensin II receptor	Type-1 angiotensin II receptor antagonist	ANTAGONIST	https://conductscience.org/library/genes/185

Source ChEMBL

Diseases65

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
hypertensive disorder	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	217	122	https://conductscience.org/library/drugs?q=MONDO_0005044
heart failure	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	85	55	https://conductscience.org/library/drugs?q=MONDO_0005252
essential hypertension	Phase 3	ClinicalTrials.gov	24	24	https://conductscience.org/library/drugs?q=MONDO_0001134
chronic kidney disease	Phase 3	ClinicalTrials.gov	9	9	https://conductscience.org/library/drugs?q=MONDO_0005300
congestive heart failure	Approval	DailyMed	30	7	https://conductscience.org/library/drugs?q=MONDO_0005009
myocardial infarction	Approval	DailyMed	75	5	https://conductscience.org/library/drugs?q=MONDO_0005068
cardiovascular disorder	Approval	ATC	6	5	https://conductscience.org/library/drugs?q=MONDO_0004995
diabetic kidney disease	Phase 2	ClinicalTrials.gov	5	5	https://conductscience.org/library/drugs?q=MONDO_0005016
type 2 diabetes mellitus	Phase 3	ClinicalTrials.gov	5	5	https://conductscience.org/library/drugs?q=MONDO_0005148
COVID-19	Phase 3	ClinicalTrials.gov	4	4	https://conductscience.org/library/drugs?q=MONDO_0100096

1 to 10 of 65Source Open Targets

See all 65 diseases

Trials451

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 4 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 43 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT00097786	Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications	Phase 3	9,306	2011-05-24	valsartan	Its name	ClinicalTrials.gov
NCT01035255	This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure	Phase 3	8,442	2015-09-07	sacubitril-valsartan	A combination that names it	ClinicalTrials.gov
NCT02924727	Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI	Phase 3	5,669	2023-06-22	valsartan	Its name	ClinicalTrials.gov
NCT01920711	Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction	Phase 3	4,822	2020-09-29	sacubitril/valsartan, valsartan	Its name	ClinicalTrials.gov
NCT00149227	Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study)	Phase 4	3,031	2012-12-12	valsartan	Its name	ClinicalTrials.gov
NCT03066804	A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients	Phase 3	2,572	2021-02-08	sacubitril/valsartan	A combination that names it	ClinicalTrials.gov
NCT00902304	Valsartan Intensified Primary Care Reduction of Blood Pressure Study	Phase 4	2,337	2012-08-30	valsartan	Its name	ClinicalTrials.gov
NCT00425373	Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension	Phase 2/3	1,474	2011-02-04	valsartan	Its name	ClinicalTrials.gov
NCT00549770	Efficacy and Safety of LCZ696A in Patients With Essential Hypertension	Phase 2	1,334	2015-08-10	valsartan	Its name	ClinicalTrials.gov
NCT00696436	An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.	Phase 3	1,291	2011-04-19	valsartan	Its name	ClinicalTrials.gov

1 to 10 of 451

See all 451 trials

Comparisons in its trials77

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
LCZ696 vs Enalapril: serious adverse events	1,937 of 4,203	2,142 of 4,229	8,432	NCT01035255	Trial comparisons
LCZ696 vs Enalapril: Number of Patients With First Confirmed Renal Dysfunction	94 of 4,187	108 of 4,212	8,399	NCT01035255	Trial comparisons
LCZ696 vs Enalapril: Number of Patients - All-cause Mortality	711 of 4,187	835 of 4,212	8,399	NCT01035255	Trial comparisons
LCZ696 (Sacubitril/Valsartan) vs Ramipril: Number of Participants With a Confirmed Composite of HF Hospitalization or Outpatient HF	201 of 2,830	237 of 2,831	5,661	NCT02924727	Trial comparisons
LCZ696 (Sacubitril/Valsartan) vs Ramipril: Number of Participants With a Confirmed Composite of CV Death or HF Hospitalization	308 of 2,830	335 of 2,831	5,661	NCT02924727	Trial comparisons
LCZ696 (Sacubitril/Valsartan) vs Ramipril: All-cause Mortality for Full Analysis Set (FAS)	213 of 2,830	242 of 2,831	5,661	NCT02924727	Trial comparisons
LCZ696 (Sacubitril/Valsartan) vs Ramipril: Number of Participants With a Confirmed Composite of CV Death, Non-fatal Spontaneous Myocardial Infarction or Non-fatal Stroke	315 of 2,830	349 of 2,831	5,661	NCT02924727	Trial comparisons
LCZ696 vs Valsartan: All-cause Mortality	342 of 2,407	349 of 2,389	4,796	NCT01920711	Trial comparisons
Valsartan vs Non-ARB: serious adverse events	0 of 1,517	0 of 1,514	3,031	NCT00149227	Trial comparisons
Valsartan/Amlodipine 160/5 mg vs Amlodipine 10 mg: serious adverse events	11 of 592	8 of 591	1,183	NCT00437645	Trial comparisons

1 to 10 of 77

See all 77 comparisons in its trials

Papers from its trials395

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39082399	RESULT	1	PubMed
37176563	RESULT	1	PubMed
37149565	RESULT	1	PubMed
36356631	RESULT	1	PubMed
35460884	RESULT	1	PubMed
34102018	RESULT	1	PubMed
33932120	RESULT	1	PubMed
33832352	RESULT	1	PubMed
33447845	RESULT	1	PubMed
33186500	RESULT	1	PubMed

1 to 10 of 395

See all 395 papers from its trials

Tests in its trials0

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL1069

GET https://conductscience.org/api/drugs/v1/CHEMBL1069/diseases?page=2

API reference For AI assistants